(Vienna—August 7, 2022, 10:10 a.m. CEST)—The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
Sugemalimab is a full-length, fully human IgG4 monoclonal antibody targeting PD-L1. GEMSTONE-301 is an ongoing phase 3 trial to evaluate sugemalimab as a consolidation treatment in patients with unresectable stage III non-small cell lung cancer without disease progression following chemoradiotherapy. The trial is the first phase 3 study in this setting to include patients who received either concurrent or sequential chemoradiotherapy. Previously, in the pre-planned progression-free survival interim analysis, sugemalimab showed a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo (Lancet Oncol. 2022 Feb;23(2):209-219).
